Abstract
PGs produced from arachidonic acid by the action of cyclooxygenase enzymes play a pivotal role in the regulation of both inflammatory and immune responses. Because leukotriene B4 (LTB4), a product of 5-lipoxygenase (5-LO) pathway, can exert numerous immunoregulatory and proinflammatory activities, we examined the effects of PGs on LTB4 release from dendritic cells (DC) and from peritoneal macrophages. In concentration-dependent manner, PGE1 and PGE2 inhibited the production of LTB4 from DC, but not from peritoneal macrophage, with an IC50 of 0.04 microM. The same effect was observed with MK-886, a 5-LO-activating protein (FLAP)-specific inhibitor. The decreased release of LTB4 was associated with an enhanced level of IL-10. Furthermore, the inhibition of LTB4 synthesis by PGs was significantly reversed by anti-IL-10, suggesting the involvement of an IL-10-dependent mechanism. Hence, we examined the effects of exogenous IL-10 on the 5-LO pathway. We demonstrate that IL-10 suppresses the production of LTB4 from DC by inhibiting FLAP protein expression without any effect on 5-LO and cytosolic phospholipase A2. Taken together, our results suggest links between DC cyclooxygenase and 5-LO pathways during the inflammatory response, and FLAP is a key target for the PG-induced IL-10-suppressive effects.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
5-Lipoxygenase-Activating Proteins
-
Adjuvants, Immunologic / pharmacology
-
Animals
-
Arachidonate 5-Lipoxygenase / biosynthesis
-
Arachidonate 5-Lipoxygenase / metabolism*
-
Calcimycin / pharmacology
-
Carrier Proteins / antagonists & inhibitors*
-
Carrier Proteins / biosynthesis*
-
Carrier Proteins / physiology
-
Cells, Cultured
-
Cyclooxygenase Inhibitors / pharmacology
-
Cytosol / enzymology
-
Dendritic Cells / drug effects
-
Dendritic Cells / enzymology
-
Dendritic Cells / metabolism*
-
Dinoprostone / pharmacology
-
Eicosanoids / biosynthesis
-
Group IV Phospholipases A2
-
Immune Sera / pharmacology
-
Interleukin-10 / biosynthesis
-
Interleukin-10 / immunology
-
Interleukin-10 / pharmacology
-
Interleukin-10 / physiology*
-
Leukotriene B4 / antagonists & inhibitors*
-
Leukotriene B4 / biosynthesis*
-
Leukotriene B4 / metabolism
-
Leukotriene B4 / pharmacology
-
Macrophages, Peritoneal / drug effects
-
Macrophages, Peritoneal / enzymology
-
Macrophages, Peritoneal / metabolism
-
Membrane Proteins / antagonists & inhibitors*
-
Membrane Proteins / biosynthesis*
-
Membrane Proteins / physiology
-
Mice
-
Mice, Inbred BALB C
-
Nuclear Envelope / drug effects
-
Nuclear Envelope / enzymology
-
Phospholipases A / biosynthesis
-
Phospholipases A / metabolism
-
Phospholipases A2
-
Prostaglandin-Endoperoxide Synthases / biosynthesis
-
Prostaglandin-Endoperoxide Synthases / physiology
-
Prostaglandins / physiology*
-
Protein Transport / drug effects
-
Signal Transduction / drug effects
-
Signal Transduction / immunology
Substances
-
5-Lipoxygenase-Activating Proteins
-
Adjuvants, Immunologic
-
Alox5ap protein, mouse
-
Carrier Proteins
-
Cyclooxygenase Inhibitors
-
Eicosanoids
-
Immune Sera
-
Membrane Proteins
-
Prostaglandins
-
Interleukin-10
-
Leukotriene B4
-
Calcimycin
-
Arachidonate 5-Lipoxygenase
-
Prostaglandin-Endoperoxide Synthases
-
Phospholipases A
-
Group IV Phospholipases A2
-
Phospholipases A2
-
Dinoprostone